Minerva Neurosciences, Inc.
NERV- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001598646
No open-market purchases or sales by Minerva Neurosciences, Inc. insiders were filed in the last 90 days; 61 institutions reported holding it in 13F filings for Q2 2026, worth $234.8M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Minerva Neurosciences, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 23 | 25 | +2 |
| Shares | 2.27M | 2.03M | −240.8K (−10.6%) |
| Value | $7.51M | $18.7M | +$11.2M (+149.5%) |
New holders (7)
Institutions that held Minerva Neurosciences, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Artal Group S.A. | 250,000 | $2.31M | 0.12% |
| Point72 Asset Management, L.P. | 25,000 | $231.0K | 0.00% |
| Truist Financial Corp | 11,043 | $102.0K | 0.00% |
| Bank of Montreal | 10,000 | $97.0K | 0.00% |
| Lazard Asset Management LLC | 2,084 | $19.0K | 0.00% |
| Royal Bank of Canada | 1,181 | $11.0K | 0.00% |
| Northwestern Mutual Wealth Management Co | 100 | $1.00K | 0.00% |
Sold out (5)
Institutions that held Minerva Neurosciences, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| SEI Investments Co | 37,998 | $126.0K |
| Barclays PLC | 8,430 | $28.0K |
| Tower Research Capital LLC (TRC) | 3,995 | $13.0K |
| Citigroup Inc | 2,125 | $7.00K |
| Simplex Trading, LLC | 251 | $0 |